Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by HippygirL74on Feb 18, 2013 3:58pm
277 Views
Post# 21006226

RE: RE: I want to believe ...

RE: RE: I want to believe ...

buy4now, the shareprice will depend on how much advantage over Voltaren Gel, the new Pennsaid 2% has, either clinically proven or perceived.  Ten cents is way too low for a drug with a long patent life.  If we get twice a day labelling, and IF the drug is safe with lotions and sunscreens, that is an amazing advantage which i am sure our American partner will capitalize on.  It will not be at 10 cents. It will instead gap up.  The exact price?  Who knows but there is nothing wrong with setting a target price you are happy with. So remember, the sp will depend on how much of an advantage over our competitor, Voltaren Gel, we will have. 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities